SIBO and Diverticular Disease: The Overlooked Connection

Diverticular disease affects roughly 50% of people over age 60 in Western countries, making it one of the most common structural GI conditions in the population. SIBO is estimated to affect 6-15% of the general population, with much higher rates in people with underlying GI disorders. The overlap between these two conditions has been quietly documented in the medical literature for decades but rarely discussed in clinical practice — partly because the focus in diverticular disease typically falls on episodes of acute diverticulitis, and SIBO management gets left on the table. But diverticula are not just passive pockets that occasionally get infected. They are structural disruptions to the normal gut architecture that can harbor bacterial colonies, create motility dead zones, and generate post-inflammatory scarring that affects small bowel function long after any acute episode has resolved. If you have diverticular disease and unexplained bloating, gas, diarrhea, or abdominal discomfort, SIBO deserves serious consideration.

What Are Diverticula and How Do They Affect Gut Function?

Diverticula are small pouches — typically 0.5-1cm — that bulge outward through weak points in the intestinal wall. The vast majority form in the colon, particularly the sigmoid colon, though they can form anywhere in the GI tract. Colonic diverticula develop when high intraluminal pressure — typically from a low-fiber Western diet that produces small, hard stools requiring forceful peristalsis — pushes the mucosal lining through small gaps in the muscle layer where blood vessels penetrate. This is diverticulosis — the mere presence of diverticula without inflammation. Most people with diverticulosis never develop symptoms or complications.

Diverticulitis — inflammation or infection of a diverticulum — occurs when fecal material or bacteria become trapped in a diverticulum, triggering local inflammation that can range from microscopic to frankly infected and abscess-forming. About 15-20% of people with diverticulosis will develop at least one episode of diverticulitis in their lifetime. Recurrent diverticulitis, complicated diverticulitis (abscess, perforation, fistula), and post-diverticulitis syndrome (persistent symptoms after inflammation resolution) represent the spectrum of clinical disease that gastroenterologists manage.

Diverticula as Bacterial Reservoirs: The Direct Mechanism

The most direct connection between diverticular disease and SIBO involves diverticula themselves serving as bacterial reservoirs. While colonic diverticula are anatomically in the colon — not the small intestine — they create conditions that affect the broader intestinal microbiome in ways that can promote overgrowth. The blind-ending pouches of diverticula have impaired self-cleaning: fecal material can stagnate in them, creating a microenvironment where bacterial populations can establish themselves at higher densities than the surrounding mucosa. This persistent bacterial colonization in diverticula generates ongoing immune stimulation, altered mucosal permeability, and changes in gut motility patterns that may affect adjacent bowel segments.

When diverticula develop in the small intestine — which occurs far less commonly than colonic diverticula but is well-documented, particularly in the duodenum and jejunum — the direct SIBO risk is immediate and mechanistically clear. Small intestinal diverticula are true SIBO-promoting structures: blind-ending pouches in the small bowel that cannot be cleared by the migrating motor complex, providing permanent bacterial reservoirs in the segment of gut where overgrowth is most clinically significant. Jejunal diverticulosis, in particular, is strongly associated with SIBO and malabsorption, and has been recognized as a SIBO risk factor since the early descriptions of the 'blind loop syndrome' in the surgical literature of the 1950s.

Post-Diverticulitis Adhesions and Structural Motility Disruption

Even when diverticular disease is entirely confined to the colon, recurrent episodes of diverticulitis can indirectly promote SIBO through their consequences on surrounding anatomy. Diverticulitis triggers peritoneal inflammation — sometimes localized, sometimes diffuse — that heals with fibrotic adhesion formation. These adhesions are bands of scar tissue that can tether bowel loops to each other, to the abdominal wall, or to the pelvis. Adhesive tethering of the small intestine creates angulations and partial obstructions that impair bacterial clearance: food and bacteria pool proximal to the obstruction, the MMC cannot effectively sweep through angulated segments, and bacterial colonization establishes itself in the stagnant zone.

Post-surgical adhesions — which occur in patients who have undergone sigmoid colectomy or Hartmann's procedure for complicated diverticulitis — are an even more potent SIBO risk factor. Abdominal surgery reliably generates adhesions, and the more extensive the surgery, the more significant the adhesion burden. Research on post-operative SIBO rates consistently shows that prior abdominal surgery is one of the strongest independent predictors of SIBO development, and diverticulitis-related surgery adds specific structural distortion of the left colon and adjacent small bowel segments.

The Fiber Paradox: Why Standard Dietary Advice May Backfire

The standard dietary recommendation for diverticular disease — high-fiber diet — is based on evidence that dietary fiber reduces intracolonic pressure, decreases transit time, and reduces the risk of diverticulitis episodes. This advice is correct for managing diverticular disease as a colonic condition. But for patients who have concurrent SIBO, high-fiber dietary recommendations create a genuine paradox.

Dietary fiber — particularly fermentable fiber (FODMAPs, inulin, psyllium) — is the primary fuel for small intestinal bacteria in SIBO. Patients with coexisting diverticular disease and SIBO who follow high-fiber recommendations may notice that their digestive symptoms worsen despite 'correct' dietary behavior. Bloating, gas, and abdominal cramping may intensify as fiber feeds the overgrown bacterial population. This creates clinical confusion: the patient is doing what their gastroenterologist recommended for their diverticular disease, but their gut symptoms are getting worse because the recommendation is correct for one condition and counterproductive for the other.

Resolving this paradox requires treating both conditions in sequence. SIBO should be treated first with antibiotics, normalizing the small intestinal bacterial population. Once SIBO is cleared, gradual reintroduction of dietary fiber — starting with non-fermentable fiber (psyllium husk, methylcellulose) before fermentable fibers — allows the colon to benefit from fiber's protective effects without continuously re-feeding a SIBO bacterial load. Working with a dietitian experienced in both diverticular disease and SIBO management can be tremendously helpful in navigating this dietary complexity.

Rifaximin: The Drug That Bridges Both Conditions

Rifaximin occupies a unique position in the management of the diverticular disease-SIBO overlap. It is used for multiple indications across this clinical territory. For SIBO, rifaximin 550mg three times daily for 14 days is the primary treatment, particularly for hydrogen-dominant SIBO. For uncomplicated diverticular disease, European guidelines recommend rifaximin 400mg twice daily as cyclical therapy (one week per month) to reduce symptoms and prevent diverticulitis recurrence — an approach supported by multiple randomized controlled trials.

For patients with both conditions, rifaximin therapy designed for SIBO treatment may simultaneously provide diverticular disease benefit — though the dosing and duration used for SIBO (higher dose, shorter course) differs from the cyclic prophylaxis used for diverticular disease. Discussing a combined treatment strategy with a gastroenterologist experienced in both conditions is the appropriate path. The diagnostic workup should include a breath test to confirm SIBO and establish a baseline, combined with careful evaluation of diverticular disease severity through colonoscopy or CT colonography to characterize the structural burden.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.